Home/Filings/4/0001209191-20-001176
4//SEC Filing

Lafond Kevin G 4

Accession 0001209191-20-001176

CIK 0001107421other

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 5:09 PM ET

Size

7.9 KB

Accession

0001209191-20-001176

Insider Transaction Report

Form 4
Period: 2019-12-31
Lafond Kevin G
Vice Pres., Treasurer, & CAO
Transactions
  • Award

    Employee Stock Option (right to buy)

    2019-12-31+48,00048,000 total
    Exercise: $4.72Exp: 2029-12-31Common Stock (48,000 underlying)
  • Sale

    Common Stock

    2020-01-02$4.55/sh21,570$98,14463,985 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019.

Issuer

ZIOPHARM ONCOLOGY INC

CIK 0001107421

Entity typeother

Related Parties

1
  • filerCIK 0001429559

Filing Metadata

Form type
4
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 5:09 PM ET
Size
7.9 KB